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1 Abstract 
Traumatic brain injury (TBI) is a leading cause of death and disability around the world, 
making it a major public health concern. The post-injury condition is marked by a complex, 
pathophysiological nature and wide-ranging physical, emotional, and cognitive symptoms. We 
hope to explore the connection, if any, between interleukin-6 (IL-6) levels and patient recovery 
following a head injury in pediatric patients. Essentially, we predict that higher IL-6 levels would 
correspond with more unfavorable patient outcomes following injury, and this relationship would 
be found to be more robust in TBI participants. To forward this objective, we used serum IL-6 
samples and three surveys completed at baseline, 3 months, and 6 months since the initial hospital 
visit. We compared these values to a set of pediatric orthopedic controls to isolate TBI-specific 
biomarker-outcome interactions. Thus far, our findings indicate that IL-6 levels are a poor 
predictor for patient post-injury outcome for TBI cases and a moderately good predictor in 
orthopedic controls. Yet, on average, participants who reported worse outcomes had higher IL-6 
levels, even across both groups. These findings allow for us to understand how certain biomarkers, 
such as IL-6, may play a role in predicting TBI-specific recovery in pediatric patients. 
 
2  Introduction 
Traumatic brain injury (TBI) is an acute cranial condition that is often marked by loss of 
consciousness and/or alteration of mental status due to blunt, physical damage and/or piercing 
entry into brain tissue (Morita, et.al. 2017). Afflicting all demographic groups, an estimated 
288,000 hospitalizations and 56,800 deaths will be related to TBI annually (Center for Disease 
Control and Prevention, 2019). Despite this, the complex pathophysiological nature of cranial 
trauma presents a clinical challenge to understand the chronic and sometimes progressive 
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symptoms that manifest unequally among affected patients (Vassar, et. al. 2014). In this sense, a 
more robust comprehension of its symptoms, underlying causes, and eventual outcomes is 
necessary to determine the proper course of action for proper prognosis, drug development, and 
psychosocial treatment.  
Despite decades of clinical study, the body of research surrounding TBIs have 
disproportionately surrounded the neuropathology of adult TBI rather than their pediatric 
counterparts (Figaji, 2017). Due to these age-related differences in brain development, post-injury 
consequences may reveal dissimilarities with the pathophysiology of adult TBI compared to 
pediatric TBIs (Madikians, et al. 2007). Proper diagnosis and therapy that are restricted to the 
specific pathological condition of a pediatric patient is greatly needed. It is paramount to discern 
the variation among pediatric TBI victims against the adult population in order to accomplish more 
targeted care.   
When subject to physical stresses, neuro-inflammatory mechanisms are put into motion 
that are primarily supported through the intracranial production of interleukins, other cytokines, 
and various additional inflammatory proteins. Used to stimulate blood flow and remove damaged 
tissues, the process by which interleukin-6 (IL-6) promotes inflammation involves the activation 
of various regenerative systems and the recruitment of additional protein and cellular factors that 
aid in the restorative management of disease or damage (Rose-John et. al., 2011). In this case, IL-
6 offers itself as an ideal candidate to measure relative extent of inflammation in a patient and the 
aftereffects observed following a TBI or an orthopedic injury.  
Self-reported health surveys present valid means to accurately account various 
psychological and physical states at a given time (Segerstrom et. al., 2016). Combined with IL-6 
levels taken from pediatric patients, self-reported health outcomes are crucial to understand any 
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potential psychiatric comorbidities that may be expressed following the distressing experience of 
a TBI. Taken together, these measures assess the interplay between IL-6 concentration, current 
psychosomatic conditions, and future predictors of prognosis and health consequences.   
In this present study, serum IL-6 levels and self-rated health measures were taken from 
both TBI-related pediatric cases and pediatric orthopedic injury controls. With the aim of 
understanding the differences in IL-6 levels predicting overall health outcome between TBI cases 
and orthopedic controls, our overarching objective was to understand the particular role of IL-6 
that is primarily in TBI rather than a more generic bodily injury. As well, we hope to report any 
discernible differences in IL-6 levels that are specific to certain demographic groups and 




3.1 Study Design Overview 
This study is a prospective, observational study in humans. We approached and enrolled 
participants ranging from age five to sixteen with either head or orthopedic injuries for the cases 
and control group, respectively. Blood tube collections and multiple parent proxy and pediatric 
surveys were completed in order to enroll in the study. Blood was then processed and stored in the 
form of serum to measure IL-6 concentrations using a single-plex immunoassay instrument, 
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3.2 Participant Enrollment 
 
3.2.1 Inclusion and Exclusion Criteria 
Participant enrollment required the fulfillment of certain inclusion and exclusion criteria. 
The following inclusion were: (1) the participant must be within five to sixteen years of age at the 
time of enrollment, (2) the visit reason must be indicative of possible head injury, brain injury, 
concussion for TBI cases and possible fracture, sprain, contusion, or unspecified bodily trauma for 
orthopedic controls, and (3) the injury must have had to occur within the past twenty-four hours 
prior to enrollment. Exclusion criteria included: (1) previous diagnosis of any significant cranial 
or orthopedic injuries, (2) current or recent use of anti-inflammatory medicines or treatments, and 
(3) major developmental or chronic disorders such as microcephaly, severe cognitive impairment, 
diabetes, and any inflammatory conditions such as juvenile arthritis.   
 
3.2.2 Consenting Process 
Following authorization by the International Review Board, potential participants were 
enrolled in the emergency department at Dell Children’s Medical Center in Austin, Texas. All 
approaches were conducted by undergraduate and health professional volunteers who had 
completed the requisite training and background checks to enroll all cases and controls. Once 
agreeing to join the study, the participant is asked to fill out parental proxy and pediatric surveys 
through a secure portal and prepare for a blood draw performed by a registered nurse, licensed 
phlebotomist, or patient care technician. 
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3.3 Survey Collection 
Surveys were generated by Patient Reported Outcome Measurement Information System 
(PROMIS) and Neurological Quality of Life (NeuroQoL) surveys, a National Institute of Health-
developed and validated tool, which focuses on eight topics. These consist of five PROMIS 
surveys completed by both a parent proxy and pediatric participants that included depressive 
symptoms, anxiety, psychological stress, positive affect, and global health. Three NeuroQoL 
surveys were administered and completed by the pediatric participant that consisted of fatigue, 
cognitive function and social relations assessments. Surveys were between six to nine questions in 
length and took between five and ten minutes to complete each one. Copies of each survey are 
located in the Appendix section. 
 
3.4 Biospecimen Processing and Storage 
Blood will be collected into the blood collection tube and inverted at least 5 times, 
incubated upright for 30-45 minutes. Collected blood was placed in a biohazard bag for transport 
to the laboratory and processing. 
After blood has been collected, the tube will be inverted 5-6 times and is left to stand in an 
upright position for 30-45 minutes to allow for clotting. Once evidence for clotting is observed, 
the tube will be centrifuged at 3500 RPM for 5 minutes. If the sample appears to be turbid, it will 
be centrifuged once more. Once turbidity is not present, the supernatant, or serum, is aspirated into 
750 uL aliquots into individual cryovials using a transfer pipette. 
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3.5 IL-6 Measurement using ELISA 
 
3.5.1  Standard Curve Preparation 
This study prepared the standard curve in a 12-channel reagent reservoir. A 1:3 serial 
dilution was performed for standards 2 through 5 and 1:2 serial dilutions for standards 6 through 
11 to achieve a curve from 50 pg/mL to 0.1 pg/mL with Standard 12 acting as the blank. 
 
3.5.2 Plate 1 Capture, Prep, and Wash 
Following the serial dilution, 75 µL of the standards were pipetted per well onto the assay 
plate. Following mixing of the coated beads, immediately before adding to the assay plate, this 
study added 550 µL of magnetic coated beads to 10.5 mL of supplied assay buffer. The bead vial 
was rinsed with 0.55 mL of assay buffer for complete bead transfer, and 100 µL of beads was 
aliquoted onto the assay plate. This plate was covered with clear adhesive plate seal, and incubated 
for 2 hours at 25°C on a microplate shaker at 875 RPM. Approximately 10 minutes prior to the 
end of target capture incubation, the detection antibody was prepared. Following incubation, the 
plate was centrifuged at 1,100 x g for 1 minute and washed with an automated plate washer. 
 
3.5.3 Detecting, Washing, Shaking, and Aspirating 
After removal from the plate washer, 20 µL per well of detection antibody was dispensed 
without disturbing the bead pellet. The assay plate was sealed with clear adhesive plate seal, 
incubated for 1 hour at 25°C on a microplate shaker at 1000 RPM, and washed four times on an 
automated plate washer. 
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After a four-cycle pre-transfer wash, the plate was placed on a microplate/incubator shaker 
for 90 seconds at 750 RPM. Once removed the plate shaker, the clear adhesive plate seal was 
carefully removed to avoid splashing and placed it on the plate washer to perform final aspiration 
of the sample. 
 
3.5.4 Elution Buffer and Final Incubation 
Next, we dispensed 10 µL Elution Buffer B per well using reverse pipetting without 
disturbing the bead pellet, incubated plate for 10 minutes at 25°C on a microplate incubator/shaker 
at 1000 RPM. The plate was then incubated for 2 minutes prior to transfer to the 384-well plate. 
A glass-bottomed 384-well Aurora plate was used for final transfer, in which 10 uL of 
Buffer D was added, followed by 10 uL of eluate from the first plate. This plate was covered with 
an aluminum seal and centrifuged at 1,100 x g for 5 minutes. 
After the immunoassay instrument, SMCxPRO, equilibrated its internal temperature, the 
assay plate was placed inside the machine and analyzed, taking about 30 minutes until completion. 
 
3.6 Statistical Analysis 
All analyses were conducted using Microsoft Excel 2016 and R Studio. Independent 
sample t tests, Pearson regression analysis, and one-way ANOVA tests were conducted for all 
continuous variables. Serum IL-6 concentration, baseline, three month, and six month survey 
outcome parameters were presented as either number (percentage), mean (± SD), or median 
(interquartile range [IQR]), wherever appropriate. To be considered different, the group difference 
had to have a p value of < 0.05 on outcome variables. All t-scores from PROMIS and NeuroQoL 
Guerrero | 10  
outcome surveys were generated through the HealthMeasures Scoring Tool, a national database 
that compares this study’s outcome values with general and clinical reference populations. Percent 
changes were calculated as a relative comparison between one t-score with a previous t-score to 
measure shift in responses over time. 
4 Results 
 
4.1 Demographic Profile 
A total of 68 participants (54.4% of them male) with a mean age 11.17 years, with an age 
range of 5 through 16 years were analyzed for the current study (Table 1). The average IL-6 
concentration in the cohort, taken holistically, is 2.49 pg/uL. Head or orthopedic injuries were 
mostly evenly distributed among accidents (33.8%), fall (29.4%), and sports-related reasons 
(32.4%), with only 4.4% being admitted into the hospital due to assault. Hispanics comprised 
47.1% of the cohort and 72.1% of the population were white.    
 
4.2 Exclusions and Survey Profile 
Out of the 74 participants who were currently enrolled in the study, four of them were 
excluded due to failing to complete a baseline survey and another two were excluded as extremely 
high outliers, for a final sample size of 68. For the 3-month surveys, 38 were finalized, with 26 
surveys completed by cases and another 12 finished by controls. For the 6-month survey, a total 
of 28 surveys were completed, as 20 were completed by the cases and another 8 by the controls. 
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4.3 Outcome Stratified by IL-6 Concentrations 
Given by a percent change in outcome, a more negative score indicates worse outcome and 
a higher positive score indicates a better outcome. When measuring case baseline to 3-month 
percent change in self-reported outcome, IL-6 concentrations were significant predictors of overall 
anxiety values (p < 0.01). While weakly significant, pediatric psychological stress and positive 
affect were relatively predictive by IL-6 concentrations (r2 = 0.123 / p < 0.173; r2 = 0.122 / p < 
0.433). Likewise, a percent change between case pediatric baseline and 6 months was significant 
for pediatric positive affect outcomes that was reasonably robust in its predictive nature (r2 = 0.153 
/ p < 0.021). 
As well, IL-6 concentrations are also a predictor in the parental global health surveys 
completed by the control group, as the percent change from baseline to 3 months shows a negative 
trend of -6.74%, p < 0.002). Also, IL-6 concentration was significant in determining the overall 
percent change of pediatric social relations and positive affect in the control group, showing a -
10.73% and a -7.94% change from baseline to 3 months (p < 0.001, p < 0.003). 
Lastly, the percent change from baseline to 6 months in the control group shows the most 
significant effects in the parental anxiety and pediatric psychological stress, with a -13.58% and a 
-6.71% decrease in overall wellbeing (p < 0.012, p < 0.018). During the same period, a percent 
change of -4.30% was also observed for the pediatric global health survey (p < 0.002). 
 
4.4 IL-6 Concentrations Stratified by Age and Sex 
Split into three subsets, child (5-9 years), preteen (10-12 years), and teen (13-16 years), 
there was no difference between the groups (p < 0.501) or when further stratified by cases and 
controls (p < 0.103, p < 0.132, p < 0.193). 
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No difference between male and females as a collective group (p < 0.342) or when 
separated based on cases or controls (p < 0.324, p < 0.492). 
 
4.5 IL-6 Concentrations Stratified by Ethnicity and Race 
As well, there were no differences between Hispanic and non-Hispanics groups when taken 
as a collective (p < 0.425) or when separated based on cases or controls (p < 0.452, p < 0.104). 
Likewise, using one-way ANOVA, there were no significant differences between races taken as a 
whole (p < 0.121), or when separated by cases or controls (p < 0.183, p < 0.495, p < 0.249). 
 
4.6 IL-6 Concentrations Stratified by Mechanism of Injury 
There was a significant difference in IL-6 levels when comparing the mechanism of injury 
as a total cohort, with those admitted into the hospital due to accidents having higher IL-6 
concentrations (4.13 pg/uL) relative to other causes of injury. This difference is made more 
apparent when comparing the case and control groups together, as controls had increased levels of 




5.1 Outcome Stratified by IL-6 Concentrations 
As there were little relative percent change for the case pediatric baseline to 3-month 
psychological stress and positive affect surveys, -2.37% and 2.54% respectively, there was also a 
low degree of predictive power of IL-6 levels with its subsequent outcome. Here, with an r2 value 
of 0.123 and 0.122, respectively, it was noted that a higher concentration of serum IL-6 mildly 
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predicted a worse outcome for the pediatric participants documenting their own wellbeing (Figure 
1). This is consistent with the background literature as IL-6 plays a significant role in determining 
overall welfare, as seen here by the pediatric self-reporting (Gill et. al. 2018). Most parental proxies 
and pediatric surveys, however, showed a negative percent change with relatively little predictive 
power, such as the percent change found in pediatric anxiety (Figure 2).  
With a relatively large positive percent change for pediatric positive affect (11.25%) from 
baseline to 6 months, there was a significant relation between lower IL-6 levels and a better self-
reported outcome (p < 0.021, Figure 3). As IL-6 levels increase, there is little or negative 
improvement in the participant’s positive outlook. This is consistent with a lower baseline of IL-6 
predicting a more robust, positive outcome (Wagner, et. al. 2014). 
For the control group reporting between baseline and 3 months, there were significant 
percent changes self-reported by the pediatric participant, as depressive symptoms, psychological 
stress, and social relations had stark, negative percent changes (-5.29%, -7.94%, and -10.73%, 
respectively). These surveys had significant differences within the population that indicated 
similar trends with the control group (p < 0.014, p < 0.003, p < 0.001), yet lacked significant 
predictive power through the levels of IL-6 concentrations, with the exception of pediatric 
depressive symptoms (Figure 4). However, this finding is not consistent with the basis of higher 
IL-6 levels predicting a worse outcome, as this trend proved quite the opposite. This may have 
been due to sampling error as a relatively low sample size of 20 was used. 
When comparing the relative percent change outcomes for control groups between baseline 
and 6 months, there were significant differences in the pediatric responses for psychological stress, 
global health, and cognitive function (-6.71%, -4.30% and 23.60%). Yet, much like the self-reports 
between baseline and 3 months, there was little predictive power between IL-6 concentrations and 
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outcome measures. As, pediatric social relation outcomes showed a high predictive strength 
between the serum biomarker and a more positive outcome. However, due to a very small sampling 
size of 8, any slight deviation from the normal proves to pull the r2 value away from the true value, 
which is evidenced by Figure 5 and the relatively high p-value of 0.086, indicating no significant 
difference. 
 
5.2 IL-6 Concentrations Stratified by Demographics 
There were no significant differences found within any of the demographic groups when 
taken as a whole or when separated by cases or controls (Table 2). This shows that the relative 
distributions of IL-6 concentrations were equally measured across the demographic groups and 
had no impact on any of the outcome percent changes reported by the participants or their parental 
proxies. Overall, however, there was a significant difference in IL-6 levels between the case and 
control groups (p < 0.018, Figure 6). 
 
5.3 IL-6 Concentrations Stratified by Mechanism of Injury 
When measuring the relative concentrations of IL-6 across different mechanisms of injuries 
from both groups, there was a significant difference in those who were admitted into the hospital 
due to accidents (p < 0.019). As this group primarily consists of larger impact injuries, such as 
motor vehicle accidents, horse-related, and bicycle accidents, the trauma is expected to be greater 
and thus, have higher levels of inflammatory proteins, such as IL-6 and other interleukins and 
cytokines.  
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This difference is further held when comparing the case and control groups, as the control 
group had a much higher IL-6 concentration, on average, relative to the case group (p < 0.039) 
when stratified by mechanism of injury. With concentrations of 6.21 pg/uL and 2.70 pg/uL 
respectively, the control groups admitted to the hospital due to accidents had greater levels of IL-
6 concentrations when compared to the case group, which may be indicative of the total-body 
nature of accidents attributed to large vehicle or animal accidents, contrasting local injuries 
affecting only the head and neck area, such as injuries relating to sports activity or falls. 
 
5.4 Limitations 
There were strong limitations within the study, with only 38 out of the 68 participants 
completing the 3-month survey and only 28 participants going on to complete their 6-month 
survey. This relatively low retention rate for survey responses proved to hinder the statistical 
strength of many of the responses and may have artificially raised the strength of others. Since the 
control group only had 8 participants with surveys completed after 6 months, any small differences 
between the values markedly skewed relative statistical significance, as 4 out of 13 surveys were 
deemed to be of noted difference and another 2 surveys were approaching significance. This lies 
in contrast to the 1 or 2 surveys presented to be of statistical significance in other time periods 
across the case and control groups, who had a more robust sampling size, buffering any potential 
distortion from individual values. 
 
6 Conclusion 
Overall, IL-6 concentrations were mild predictors in determining participant outcome over 
3 month and 6-month periods. While certain outcomes had statistical significance and a strong 
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predictive attribute, such as pediatric positive affect from baseline to 6 months, most survey 
outcomes were weakly predicted by levels of IL-6 concentrations across both case and control 
groups.   
However, many of the surveys had a robust percent change in both groups, with many of 
the changes having p-values below 0.05, across time periods. Many of the large percent changes, 
either positive or negative, were shown to have statistical significance across groups and showed 
how IL-6 concentrations may play a role in determining the relative outcome of participants 
enrolled in the study.  
Demographics played little or no role in influencing serum IL-6 levels, either across both 
groups and when taken together as a whole. This allows for this study to tentatively conclude that 
the demographic profile of the participants had no impact on the relative outcome measured by the 
surveys. However, there was a significant difference between mechanisms of injury, as those who 
suffered accidents, such as vehicle crashes or bicycle incidents, were subject to much higher IL-6 
levels in the control group. This finding may be attributed to more severe impacts related to total-
body crashes often associated with moving at relatively high speeds,  
Future work involves the use of genomic data to further elucidate the genetic difference in 
protein expression among individuals across the groups. This would allow future studies to control 
for single nucleotide polymorphisms that have an effect on overall IL-6 levels that may, in turn, 
govern pediatric and parent proxy outcome responses post-injury. As well, greater emphasis on 
patient retention in the form of survey responses is vital for the creation of a more cogent sample 
size. Moreover, greater research into other potential inflammatory proteins of interests, such as IL-
10 and amyloid beta-42, would further distinguish different serum biomarkers that may play a role 
in outcome prognosis and change. Lastly, sex-age paired case-control would control for any 
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confounding differences to create a stronger study design to measure biomarkers and their role in 
predicting patient prognosis. 
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9 Appendix 
 
  Group  
 
Total 
(N = 68) 
TBI Case 
(n = 43) 
Orthopedic 
Controls 
(n = 25) 
p-value 
Age (years, mean ± SD) 11.17 (2.92) 11.27 (2.87) 11.12 (3.05) 0.3461 
Age Range (years) (5 – 16) (5 – 16) (5 – 16)  
Sex, Male (%) 37 (54.4) 23 (53.4) 14 (53.8) 0.4539 
Ethnicity, Hispanic (%) 32 (47.1) 20 (46.5) 13 (52) 0.4392 




Accident (n, %) 23 (33.8) 15 (34.9) 8 (32) 0.3421 
Assault (n, %) 4 (4.4) 4 (6.9) 0 (0) - 
Fall (n, %) 20 (29.4) 14 (32.6) 6 (24) 0.2428 
Sports-Related (n, %) 22 (32.4) 11 (25.6) 6 (44) 0.2945 
Table 1. Demographic Comparison between Cases and Controls. Significant p-values below 
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   Group  
 
Total 





(n = 43) 
Orthopedic 
Controls 
(n = 25) 
p-value 
Age Groups       
Age 5 – 9 3.19 (3.70) 
0.501 
2.52 (3.63) 4.34 (3.31) 0.103 
Age 10 – 12  2.23 (2.39) 1.60 (1.17)  3.35 (4.49) 0.132 
Age 13 – 16  2.21 (3.19) 1.48 (2.13) 3.43 (4.96) 0.193 
Sex    
Male  2.07 (2.33) 
0.342 
1.51 (1.36) 3.07 (3.28) 0.324 
Female  2.97 (3.62) 2.17 (2.76) 4.30 (4.54) 0.492 
Ethnicity    
Hispanic  2.42 (2.92) 
0.425 
2.22 (2.81) 2.74 (3.18) 0.452 
Non-Hispanic  2.56 (3.14) 1.46 (1.23) 4.08 (4.43) 0.104 
Race    
White  2.77 (3.43) 
0.121 
1.97 (2.43) 4.17 (4.41) 0.183 
Black or African 
American  
1.63 (1.84) 1.14 (1.11) 2.63 (2.86) 0.495 




Accident  4.13 (4.46) 
0.019 
 
2.70 (3.34) 6.21 (5.22) 0.039 ** 
Assault  1.63 (1.74) 1.63 (1.74) - - 
Fall  1.79 (1.79) 1.39 (1.24) 2.97 (2.74) 0.143 
Sports-Related 1.65 (1.27) 1.42 (1.02) 1.87 (1.49) 0.429 
      
Overview (n, %) 2.49 (3.05) - 1.82 (2.13) 3.66 (3.91) 0.018*** 
Table 2. IL-6 Concentration Between TBI Case and Orthopedic Control Groups. Values 
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Figure 2. Case Pediatric Anxiety Percent Change from Baseline to 3 Months. 
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Figure 4. Control Pediatric Depressive Symptoms Percent Change from Baseline to 3 
Month 
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Figure 5. Control Pediatric Social Relations Percent Change from Baseline to 3 Month. 
 
 
Figure 6. IL-6 Levels between Cases and Controls. Statistical significance is denoted (*) for p-
values < 0.05.   
** 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PROMIS Pediatric Scale v1.0 – Global Health 7+2 
 
Pediatric Global Health 7+2 
 












Good Good Fair Poor 
Global01R1 In general, would you say your 











       
Global02R1 
In general, would you say your 











       
Global03R1 
In general, how would you rate 











       
Global04R1 
In general, how would you rate 
your mental health, including 
your mood and your ability to 












 Never Rarely Sometimes Often Always 
PedGlobal2R1 How often do you feel really 












 Always Often Sometimes Rarely Never 
PedGlobal5R1 How often do you have fun with 















How often do your parents listen 












In the past 7 days…      
  Never 
Almost  
Never Sometimes Often 
Almost  
Always 










       
3793R1r 
I had trouble sleeping when I 
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PROMIS Pediatric Item Bank v1.0 - Positive Affect – Short Form 8a 
 
 
Positive Affect – Short Form 8a 
 
 




In the past 7 days… 
 Never Rarely Sometimes Often Always 
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PROMIS Pediatric Item Bank v1.0 – Psychological Stress Experiences – Short Form 8a 
 
 
Psychological Stress Experiences – Short Form 8a 
 





In the past 7 days… 
 Never Rarely Sometimes Often Always 
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PROMIS Pediatric Item Bank v2.0 – Anxiety – Short Form 8a 
 
 
Pediatric Anxiety – Short Form 8a 
 






In the past 7 days… 
 Never 
Almost 
Never Sometimes Often 
Almost 
Always 
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PROMIS Pediatric Item Bank v2.0 – Depressive Symptoms – Short Form 8a 
 
 
Pediatric Depressive Symptoms – Short Form 8a 
 






In the past 7 days… 
 Never 
Almost 
Never Sometimes Often 
Almost 
Always 
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Neuro-QOL Item Bank v1.0 –Pediatric Social Relations- Interaction with Peers- Short form  
 
        Pediatric Social Relations- Interaction with Peers – Short Form  
 
 
Please respond to each question or statement by marking one box per row. 
 
  
In the past 7 days… Never 
Almost 
never Sometimes Often 
Almost 
always 
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Neuro-QOL Item Bank v2.0 –Pediatric Cognitive Function – Short Form  
 
      Pediatric Cognitive Function – Short Form 
 
 
Please respond to each question or statement by marking one box per row. 
 
  
 Not at all A little bit Somewhat Quite a bit Very much 










       
NQCOGped05 












       
NQCOGped08 
I react slower than most people my age 











       










       
NQCOGped17 
I have trouble remembering to do things 











       
NQCOGped18 












       
NQCOGped19 












       
NQCOGped20 
I have to work really hard to pay 
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Neuro-QOL Item Bank 2.1 –Pediatric Fatigue – Short Form  
 
 
       Pediatric Fatigue –Short Form 
 
 




In the past 7 days… None of the time 






All of the 
time 










       
NQFTGped04 












       
NQFTGped05 
I had trouble finishing things because I 











       










       
NQFTGped08 
Being tired made it hard to play or go out 
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PROMIS Parent Proxy Item Bank v1.0 - Physical Stress Experiences – Short Form 8a 
 
 
Physical Stress Experiences – Short Form 8a 
 
 




In the past 7 days… 
 Never Rarely Sometimes Often Always 
EoS_S_032_PXR1 
My child’s heart beat faster than 
usual, even when he/she was not 











       
EoS_S_033_PXR1 
My child had trouble breathing, even 
when he/she was not exercising or 











       










       
EoS_S_046_PXR1 
My child had pain that really bothered 
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PROMIS Parent Proxy Item Bank v1.0 – Positive Affect – Short Form 8a 
 
 
Positive Affect – Short Form 8a 
 
 




In the past 7 days… 
 Never Rarely Sometimes Often Always 
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PROMIS Parent Proxy Item Bank v1.0 - Psychological Stress Experiences – Short Form 8a 
 
 
Psychological Stress Experiences – Short Form 8a 
 
 




In the past 7 days… 
 Never Rarely Sometimes Often Always 










       
EoS_P_064_PXR1 
My child felt that his/her problems 











       










       
EoS_P_112_PXR1 
My child felt unable to manage things 











       










       










       










       
EoS_P_118_PXR1 
My child felt he/she had too much 
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PROMIS Parent Proxy Item Bank v2.0 – Anxiety – Short Form 8a 
 
 
Parent Proxy Anxiety – Short Form 8a 
 













In the past 7 days… 
 Never 
Almost 
Never Sometimes Often 
Almost 
Always 










       










       










       
Pf2anxiety1r 
My child felt like something awful might 











       
Pf2anxiety5r 
My child worried when he/she was at 











       










       
Pf1anxiety3r 
My child worried about what could 











       
Pf2anxiety4r 
My child worried when he/she went to 
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PROMIS Parent Proxy Item Bank v2.0 – Depressive Symptoms – Short Form 6a 
 
 
Parent Proxy Depressive Symptoms – Short Form 6a 
 






In the past 7 days… 
 Never 
Almost 
Never Sometimes Often 
Almost 
Always 










       
Pf1depr7r 
My child felt everything in his/her life 











       
Pf1depr5r 
My child felt like he/she couldn't do 
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